In this issue:
Impact of duration of induction therapy on survival in MM patients undergoing upfront ASCT
Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with RRMM
Patient-reported outcomes of MM patients treated with panobinostat in the PANORAMA-1 trial
An expanded treatment protocol of panobinostat
Impact of extramedullary disease in patients with NDMM undergoing ASCT
Elevated pre-transplant C-reactive protein identifies a high-risk subgroup of MM patients
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in MM
T Cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis RMM
A compound chimeric antigen receptor strategy for targeting MM
Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain
Please login below to download this issue (PDF)